ArticleFrontiers in oncology2026
Tetrandrine injection for preventing radiation-induced lung injury in patients with locally advanced esophageal squamous cell carcinoma: a randomized controlled trial protocol.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiation-induced lung injury (RILI) is a common and dose-limiting toxicity in patients with locally advanced esophageal squamous cell carcinoma (ESCC) receiving concurrent chemoradiotherapy (CCRT). Effective prophylactic agents are lacking. Tetrandrine, a bisbenzylisoquinoline alkaloid, has shown anti-inflammatory and anti-fibrotic properties in preclinical studies. This randomized controlled trial aims to evaluate the efficacy and safety of tetrandrine injection for preventing RILI in this population. Methods: This is a single-center, randomized, placebo-controlled, double-blind, phase II trial. A total of 100 eligible patients with locally advanced ESCC (T3-4N+M0) receiving definitive CCRT will be randomly assigned (1:1) to receive either intravenous tetrandrine (200-300 mg/day, 6 days per week for 12 weeks) or matching placebo. Radiotherapy dose is 50-50.4 Gy (1.8 Gy/fraction) using IMRT, with concurrent docetaxel/cisplatin. The primary endpoint is the incidence of grade ≥2 RILI according to CTCAE v5.0. Secondary endpoints include any-grade RILI, time to RILI onset, change in pulmonary function, and CCRT completion rate. Sample size calculation (40 evaluable per group) provides 80% power to detect a 15% absolute risk reduction (from 25% to 10%) with two-sided α=0.20. The protocol follows SPIRIT 2013 guidelines. Recruitment has not yet started. Discussion: This trial will generate preliminary evidence on the efficacy of tetrandrine for preventing RILI in ESCC patients. By adopting internationally accepted radiotherapy doses (50-50.4 Gy) and stringent lung dose constraints (V20 ≤ 30%, MLD < 20 Gy), the study provides a robust framework for comparing outcomes with global literature. Systematic review registration: https://www.chictr.org.cn/bin/project/edit?pid=289682, identifier ChiCTR2500111007.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.